Could cancer drugs be the future of Alzheimer's treatment?
Alzheimer's cases are rising in the United States and worldwide due to an aging population, but there is no cure for the disease. Attempts to develop new treatments that slow the disease's progress, rather than lessen symptoms, have frequently failed.
Only two drugs — the antibody therapies Leqembi and Kisunla — are currently approved by the Food and Drug Administration to slow the progression of early Alzheimer's, and scientists say their benefits are limited.
Some pharmaceutical companies have halted or abandoned their Alzheimer's drug development programs because of unsuccessful trials. Others are trying to use existing medications, including popular weight loss drugs, to combat Alzheimer's.
With that in mind, researchers at the University of California, San Francisco conducted a broad search for drugs that could be repurposed to treat the condition — in theory, reducing the time in which the drugs could be made available to patients. They scoured a database of more than 1,300 drugs of various classes, including antipsychotics, antibiotics, antifungals and chemotherapy drugs. Then, they looked at how those drugs affected gene expression.
Their new study, published Monday in the journal Cell, identified two cancer drugs as the best candidates to lower Alzheimer's risk in patients. When combined, the drugs seemed to slow or reverse Alzheimer's symptoms in mice. One of the drugs is normally used to treat breast cancer, while the other is effective against colon and lung cancer.
Alzheimer's disease is associated with significant changes in the way genes are expressed in the brain, leading to the increased production of certain proteins and the decreased production of others. These imbalances may disrupt brain function and contribute to symptoms like memory loss.
Fewer than 90 drugs in the researchers' database reversed the expression of signature Alzheimer's-related genes in human brain cells. And five drugs in particular seemed to lower the risk of Alzheimer's in actual patients, based on electronic medical records. The authors ultimately selected two of those drugs, both approved by the FDA to treat cancer, to test in mice.
'We didn't expect cancer drugs to come up' as the most promising, said Marina Sirota, a co-author of the study and interim director of the UCSF Bakar Computational Health Sciences Institute.
The authors said the breast cancer drug letrozole seemed to change gene expression in nerve cells. And the colon and lung cancer drug irinotecan seemed to change gene expression in glial cells, which support the nervous system. Alzheimer's can destroy nerve cells and cause glial cells to proliferate, creating inflammation in the brain.
In a 2020 study, breast cancer patients who received letrozole were less likely to develop Alzheimer's than patients who did not receive the drug. Colorectal cancer survivors treated with irinotecan also had a decreased Alzheimer's risk, according to a 2021 study.
After testing the drugs in mice, the study authors found that the two-drug combo reversed brain degeneration and improved memory in mice that had developed hallmarks of Alzheimer's as they aged.
Because results in mice often don't translate to humans, the researchers hope to test the drugs in a clinical trial with Alzheimer's patients.
'Developing a new drug can take hundreds of millions, or even billions, of dollars, on average take more than 10 years. For this repurposed drug, usually it just takes two or three years, and then you can go to the clinical trial and the cost is much, much lower,' said Dr. Yadong Huang, a co-author of the study and professor of neurology at UCSF.
'We still haven't generated or produced any very effective drugs that can really slow dramatically the cognitive decline,' he added.
Part of the difficulty in developing drugs for Alzheimer's is the complexity of the disease. Its exact cause is largely unknown.
For now, the authors said, it's unclear exactly why the cancer drugs seem to work against Alzheimer's. One theory is that the breast cancer drug blocks the production of estrogen, a hormone that controls the expression of a large number of genes. The colon and lung cancer drug may also block inflammation in the brain by preventing the proliferation of glial cells — though Huang said there are other possibilities.
Dr. Melanie McReynolds, an assistant professor of biochemistry at Pennsylvania State University, who was not involved in the study, offered another theory.
Her research has suggested that a different type of cancer drug could help treat Alzheimer's by regulating glucose metabolism, the process by which cells make energy. McReynolds said the process is necessary for various brain cells to communicate with each other.
'With aging, with stress, with diseases, that line of communication is disrupted,' she said.
McReynolds said the drug combo tested in the new study might reverse metabolic decline — what she called 'the secret for contributing to better outcomes with Alzheimer's.'
But assessing how Alzheimer's patients tolerate the combination of cancer drugs will be important. Letrozole can cause hot flashes and irinotecan can cause severe diarrhea. Both drugs can lead to nausea and vomiting.
'These drugs have huge side effects, so you need to always balance and figure out whether those types of side effects would be amenable to somebody with Alzheimer's,' Sirota said. 'It's not that it's a slam dunk.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Evening Standard
9 minutes ago
- Evening Standard
Billy Joel says he feels ‘good' after being diagnosed with brain condition
According to the NHS website, NPH is an uncommon and poorly understood condition that often affects people over the age of 60 and can be difficult to diagnose as its symptoms include mobility problems and dementia, which are associated with more common conditions such as Alzheimer's disease.
Scottish Sun
7 hours ago
- Scottish Sun
Two NHS drugs slows and could REVERSE devastating Alzheimer's, ‘exciting' study finds
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) TWO NHS drugs could be combined to treat, and even reverse, the most common form of dementia, scientists claim. A pair of cancer drugs have been identified as a powerful duo that may tackle Alzheimer's disease, after scientists sifted through 1,300 approved medicines. Sign up for Scottish Sun newsletter Sign up 1 Alzheimer's was reversed in mice Credit: Alamy The American team used cutting-edge computer tools to match the gene changes seen in Alzheimer's patients with medicines that reverse those effects. They found that two cancer drugs, both already available on the NHS, reduced brain degeneration in mice with the disease, and even brought back their memory. The study, from the University of California, San Francisco (UCSF), first looked at how Alzheimer's alters the activity of individual brain cells. They then searched for existing drugs that trigger the opposite changes, with the aim of rewiring damaged neurons and brain cells called glia. And when they tested the top two candidates, letrozole and irinotecan, in lab mice, the results were impressive. One theory of how Alzheimer's comes about is that sticky proteins - like amyloid-beta - start clumping together in the brain years before symptoms appear. These toxic clumps block communication between brain cells and trigger inflammation, eventually causing the cells to die. Some scientists believe this buildup is the root cause of Alzheimer's, so clearing it could stop the disease in its tracks. When combined, the cancer drugs not only halted brain cell damage but also undid toxic clumps of proteins, restored memory and reversed the disease's genetic footprint. Prof Marina Sirota, senior author, said: 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.' Common painkiller used for back pain ups risk of dementia by 29%, scientists warn She added: 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat — but our tools opened up the possibility of tackling that complexity directly.' The scientists then trawled through the anonymised medical records of 1.4million over-65s and found those already taking the cancer drugs were less likely to develop Alzheimer's. Dr Yaqiao Li, the study's lead author, said: 'Thanks to all these existing data sources, we went from 1,300 drugs, to 86, to 10, to just five. 'In particular, the rich data collected by all the UC health centres pointed us straight to the most promising drugs. It's kind of like a mock clinical trial.' Letrozole is typically used to treat breast cancer, while irinotecan is prescribed for colon and lung cancer. Both are already used in the UK. 'So exciting' Prof Yadong Huang, co-senior author, said: 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health. 'This makes it very challenging for drug development - which traditionally produces one drug for a single gene or protein that drives disease.' He added: 'It's so exciting to see the validation of the computational data in a widely used Alzheimer's mouse model.' The breakthrough, published in the journal Cell, could fast-track trials in humans. Prof Sirota said: 'If completely independent data sources, such as single-cell expression data and clinical records, guide us to the same pathways and the same drugs and then resolve Alzheimer's in a genetic model then maybe we're onto something.' She added: 'We're hopeful this can be swiftly translated into a real solution for millions of patients with Alzheimer's.' Alzheimer's causes a relentless decline in cognition, learning, and memory. But decades of research have only produced two FDA-approved drugs, neither of which can meaningfully slow the decline. In the UK, no disease-modifying drugs are currently approved or available. Instead, the UK relies on symptom-managing drugs, such as Donepezil and Rivastigmine.
The Sun
7 hours ago
- The Sun
Two NHS drugs slows and could REVERSE devastating Alzheimer's, ‘exciting' study finds
TWO NHS drugs could be combined to treat, and even reverse, the most common form of dementia, scientists claim. A pair of cancer drugs have been identified as a powerful duo that may tackle Alzheimer's disease, after scientists sifted through 1,300 approved medicines. 1 The American team used cutting-edge computer tools to match the gene changes seen in Alzheimer's patients with medicines that reverse those effects. They found that two cancer drugs, both already available on the NHS, reduced brain degeneration in mice with the disease, and even brought back their memory. The study, from the University of California, San Francisco (UCSF), first looked at how Alzheimer's alters the activity of individual brain cells. They then searched for existing drugs that trigger the opposite changes, with the aim of rewiring damaged neurons and brain cells called glia. And when they tested the top two candidates, letrozole and irinotecan, in lab mice, the results were impressive. One theory of how Alzheimer's comes about is that sticky proteins - like amyloid-beta - start clumping together in the brain years before symptoms appear. These toxic clumps block communication between brain cells and trigger inflammation, eventually causing the cells to die. Some scientists believe this buildup is the root cause of Alzheimer's, so clearing it could stop the disease in its tracks. When combined, the cancer drugs not only halted brain cell damage but also undid toxic clumps of proteins, restored memory and reversed the disease's genetic footprint. Prof Marina Sirota, senior author, said: 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.' She added: 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat — but our tools opened up the possibility of tackling that complexity directly.' The scientists then trawled through the anonymised medical records of 1.4million over-65s and found those already taking the cancer drugs were less likely to develop Alzheimer's. Dr Yaqiao Li, the study's lead author, said: 'Thanks to all these existing data sources, we went from 1,300 drugs, to 86, to 10, to just five. 'In particular, the rich data collected by all the UC health centres pointed us straight to the most promising drugs. It's kind of like a mock clinical trial.' Letrozole is typically used to treat breast cancer, while irinotecan is prescribed for colon and lung cancer. Both are already used in the UK. 'So exciting' Prof Yadong Huang, co-senior author, said: 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health. 'This makes it very challenging for drug development - which traditionally produces one drug for a single gene or protein that drives disease.' He added: 'It's so exciting to see the validation of the computational data in a widely used Alzheimer's mouse model.' The breakthrough, published in the journal Cell, could fast-track trials in humans. Prof Sirota said: 'If completely independent data sources, such as single-cell expression data and clinical records, guide us to the same pathways and the same drugs and then resolve Alzheimer's in a genetic model then maybe we're onto something.' She added: 'We're hopeful this can be swiftly translated into a real solution for millions of patients with Alzheimer's.' Alzheimer's causes a relentless decline in cognition, learning, and memory. But decades of research have only produced two FDA-approved drugs, neither of which can meaningfully slow the decline. In the UK, no disease-modifying drugs are currently approved or available. Instead, the UK relies on symptom-managing drugs, such as Donepezil and Rivastigmine. Is it ageing or dementia? Dementia - the most common form of which is Alzheimer's - comes on slowly over time. As the disease progresses, symptoms can become more severe. But at the beginning, the symptoms can be subtle or mistaken for normal memory issues related to ageing. The US National Institute on Aging gives some examples of what is considered normal forgetfulness in old age, and dementia disease. You can refer to these above. For example, it is normal for an ageing person to forget which word to use from time-to-time, but difficulties having conversation would be more indicative of dementia. Katie Puckering, Head of Alzheimer's Research UK's Information Services team, previously told The Sun: 'We quite commonly as humans put our car keys somewhere out of the ordinary and it takes longer for us to find them. 'As you get older, it takes longer for you to recall, or you really have to think; What was I doing? Where was I? What distracted me? Was it that I had to let the dog out? And then you find the keys by the back door. 'That process of retrieving the information is just a bit slower in people as they age. 'In dementia, someone may not be able to recall that information and what they did when they came into the house. 'What may also happen is they might put it somewhere it really doesn't belong. For example, rather than putting the milk back in the fridge, they put the kettle in the fridge.'
